A little concerned, something doesn't "feel" right.
The large shelf filing combined with recent financing, and a tepid move into this data readout has me a bit concerned that results will disappoint. And even if they don't, we could see a "sell the news" event. Thoughts?
I'm not short, just concerned that with results a day away, NSPR is underperforming. My guess is that the 12 month data will show very little difference between MGuard and traditional stents. Not because MGuard doesn't work, but because MGuard's effectiveness is protecting against plaque rupture, something that occurs during and shortly after stent placement. A year out, I'd guess that plaque rupture isn't a common event, and therefore I would expect the Mguard stent to make less difference in outcomes. I think the data that matters we've already seen. If I'm right, I'm just concerned the 12month data might cause an self-off, or worse a short raid on NSPR.